Creating and Testing a Model to Predict Postoperative Discomfort in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolisation

Background: Abdominal pain is a frequent adverse event in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE). However, there remains uncertainty regarding the determinants of post-TACE pain. Objectives: We aimed to create and verify prediction model for postoperative HCC TACE treatment. Methods: This prospective study included all undergoing our hospital. According time treatment, dataset was divided into two cohorts (development validation) 3: 2 ratio. After TACE, participants used visual analog scale quantify their level at rest over 24-hour period. The age, gender, tumor location, size number, medication administration route, presence portal vein thrombosis (PVTT) were recorded patients. Results: In total, 137 (mean age: 60.3 ± 10.1 years; 78.1% male) 91 61.1 10.5 73.6% development validation cohorts, respectively. Furthermore, 46.0% 39.6% experienced acute moderate severe drug delivery method, PVTT independently associated pain, which combined develop based on logistic equation. discrimination this risk score satisfactory both (area under curve (AUC): 0.693, 95% confidence interval (CI): 0.609 0.769, P < 0.001) (AUC: 0.652, CI: 0.544 0.748, = 0.002) cohorts. There no significant difference between (difference: 0.042, -0.081 0.164, 0.506). had good specificity predicting (83.8% (95% 73.4% 91.3%)) (76.4% 63.0% 86.8%)) Conclusions: PVTT, method factors discomfort. A these useful identifying who vulnerable further studies are required validate findings optimize model’s performance.